This site is intended for healthcare professionals residing in Canada.

Visit Pfizer AcademySearch

Menu

Close

Sign InLog Out
  • EN
ProductsTherapy AreasExplore ContentExplore
ContentGo to Explore ContentEventsMaterialsVideosPatient SupportContact
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Français

Menu

Close

About Prevnar 13About Prevnar 13Mechanism of ActionSerotype coverageIncidence of IPD and Colonization dataExperienceImmunogenicityDosingDosingDosingEfficacy and Safety ProfileEfficacy and Safety ProfileEfficacy profileSafety profileGuidelinesGuidelinesGuidelinesResourcesResourcesMaterialsVideos
Product MonographImportant Safety Information 
DosingAre your patients getting the full schedule?

In a 2015 national coverage survey, 20% of children had not received a full pneumococcal vaccination schedule by age 2.1*

Help protect your infant patients by following the recommended dosing schedule 

Pediatric schedule if Prevnar 13 is given as part of a routine immunization program2† 

TitleUse the 4-dose schedule for babies at high risk. See the Canadian Immunization Guidelines for complete list of high-risk conditions and recommendations.

With your support, a timely and complete 3- or 4-dose schedule schedule of Prevnar 13 can continue to help protect infants against IPD caused by 13 serotypes of S. pneumoniae.

IPD: invasive pneumococcal disease.Based on results from the 2015 Childhood National Immunization Coverage Survey.Please see the Canadian Immunization Guidelines for complete recommendations.Recommended dosing interval is 2 months.References:Public Health Agency of Canada. Vaccination coverage in Canadian children: Results from the 2015 Childhood National Immunization Coverage Survey (CNICS). Available at: http://publications.gc.ca/collections/collection_2018/aspc-phac/HP40-156-2018-eng.pdf. Accessed May 14, 2019.Prevnar® 13 Product Monograph. Pfizer Canada ULC. 2022.Health Canada. Canadian Immunization Guide Part 4 – Active Vaccines: Pneumococcal Vaccines. Available at: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-16-pneumococcal-vaccine.html#a7. Accessed April 29, 2019.
NEXT

Efficacy profile

 Visit page Loading
LEARN MORE

Guidelines

 Visit page Loading
PP-PRV-CAN-0016-EN

To report an adverse event, please call 1-866-723-7111

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out

© Pfizer Canada ULC 2024. All rights reserved. The information is intended only for healthcare professionals resident in Canada. ®Pfizer Inc., used under license.

PP-UNP-CAN-0145-EN
You are now leaving Pfizerpro.ca website
Links to other sites are provided as a convenience to the viewer, and should not be taken as an endorsement of the sites or an association with their owners. Pfizer Canada accepts no responsibility for the content of linked sites.
You are now leaving the PfizerPro Portal.
You are about to view resources made available by Pfizer Academy. 
These resources include learning programs and upcoming events. By selecting Go to link below, you acknowledge and certify that you are a Canadian Healthcare Professional.
PP-UNP-CAN-0013 EN